Brains Bioceutical Expands Industry-Leading Cannabinoid Offering with D9-THC and CBN, Unveiling New Frontiers for Drug Development

VANCOUVER, British Columbia, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Brains Bioceutical Corp. (Brains Bio), a global leader in natural, GMP-compliant cannabinoid Active Pharmaceutical Ingredients (APIs), announces the expansion of its industry-leading offering. Cannabinol (CBN) is available as an EU-GMP certified API, D9-Tetrahydrocanabinol (THC) is in a solid crystalline form, undergoing enhanced stability optimization work and final validation work is being undertaken on Cannabigerol (CBG). Read More

Brains Bioceutical Expands Industry-Leading Cannabinoid Offering with D9-THC and CBN, Unveiling New Frontiers for Drug Development

Brains Bioceutical Expands Industry-Leading Cannabinoid Offering with D9-THC and CBN, Unveiling New Frontiers for Drug Development

Brains Bioceutical Expands Industry-Leading Cannabinoid Offering with D9-THC and CBN, Unveiling New Frontiers for Drug Development

Brains Bioceutical Expands Industry-Leading Cannabinoid Offering with D9-THC and CBN, Unveiling New Frontiers for Drug Development

Brains Bioceutical Expands Industry-Leading Cannabinoid Offering with D9-THC and CBN, Unveiling New Frontiers for Drug Development